Are home blood pressure monitors worth it? Yes, with a validated cuff that fits

Why home readings matter: white-coat and masked hypertension

US guidelines rely on out-of-office readings to confirm a diagnosis^{2, 14}. In an individual-patient meta-analysis of 15 trials, home monitoring lowered clinic systolic pressure by 3.2 mm Hg at 12 months⁴. The benefit came mostly when monitoring was paired with medication changes, education or lifestyle counseling⁴. On its own, home monitoring made little difference⁴.

The trials measured blood pressure, not heart attacks, strokes or deaths⁴. What separates a useful monitor from a misleading one is independent validation, an upper-arm cuff in the right size and a consistent way of measuring^{5, 7, 14}. Cuffless estimates from watches and rings aren’t a validated substitute^{1, 11}.

Blood pressure measured in a clinic can differ considerably from blood pressure measured outside it¹⁴. That gap creates two blind spots. White-coat hypertension means blood pressure is high in the office but normal outside it^{2, 3}. Masked hypertension is harder to spot, and the US Preventive Services Task Force (USPSTF) says only out-of-office measurements can detect it². Screening that starts and ends with office readings can’t find it².

US guidance has moved accordingly. The USPSTF gives screening adults for high blood pressure its top “A” grade². It recommends getting measurements outside the clinical setting to confirm the diagnosis before treatment starts².

The American Heart Association (AHA) and the American Medical Association (AMA) issued a joint policy statement in 2020¹⁴. It calls self-measured home monitoring a validated way to measure blood pressure outside the office¹⁴. It notes that several US and international guidelines endorse it, both for confirming a diagnosis and for managing treated hypertension¹⁴. The 2025 AHA/ACC multisociety guideline defines stage 1 hypertension as 130 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic¹. It calls home monitoring, combined with frequent interactions with a multidisciplinary care team, an important integrated tool to improve blood pressure control¹.

It isn’t settled whether high office readings with normal readings elsewhere are harmless. A 2019 meta-analysis pooled 27 observational studies with a mean follow-up of at least 3 years³. They covered 25,786 people with white-coat hypertension or a white-coat effect on treatment, and 38,487 people with normal blood pressure³.

Untreated white-coat hypertension was associated with a higher risk of cardiovascular events (hazard ratio 1.36, 95% CI 1.03 to 2.00)³. It was also associated with a higher risk of death from any cause (1.33, 1.07 to 1.67) and of cardiovascular death (2.09, 1.23 to 4.48)³. In people already on treatment, a white-coat effect wasn’t significantly associated with any of these outcomes³. The authors concluded that out-of-office monitoring is critical to diagnosing and managing hypertension³. But the studies were observational, and unmeasured confounding is possible³.

For out-of-office confirmation, the USPSTF accepts either home monitoring or ambulatory monitoring with validated and accurate devices². It treats ambulatory monitoring as the reference standard². It also says ambulatory monitoring offers the most evidence-based risk information for future cardiovascular events².

In a pooled analysis of 4 studies with 1,001 people, home readings at a 135/85 mm Hg threshold were checked against ambulatory monitoring². Their sensitivity was 0.84 (95% CI 0.76 to 0.90)². Their specificity was 0.60 (0.48 to 0.71)². In plain terms, home readings missed about 1 in 6 people the reference test classed as hypertensive². They also flagged about 4 in 10 of those it classed as normal².

What the evidence shows: home monitoring and blood pressure control

The strongest evidence on whether home monitoring changes blood pressure is a 2017 systematic review and individual patient data meta-analysis in people with hypertension⁴. The authors identified 36 eligible randomized trials and obtained individual data from 25⁴. They analyzed 12-month results from 15 trials, covering 7,138 of 8,292 randomized participants⁴. Overall, self-monitoring lowered clinic systolic blood pressure by 3.2 mm Hg compared with usual care (95% CI 1.6 to 4.9)⁴. The catch is that results varied a lot between trials (I² = 76%), which the authors called the main limitation⁴.

The size of the benefit tracked what came with the monitor (see table). Self-monitoring with no added support changed systolic pressure by 1.0 mm Hg, a difference that wasn’t statistically significant⁴. Paired with the most intensive support, personal support throughout the trial, it lowered systolic pressure by 6.1 mm Hg⁴. The co-interventions in these trials included medication titration, education and lifestyle counseling⁴.

The authors judged the trials to be at low risk of bias overall⁴. Only 12 of the 25 trials used blinded outcome assessment⁴. A post hoc sensitivity analysis found no difference in results by blinding⁴.

The AHA/AMA statement reaches the same conclusion from the wider literature¹⁴. It says home monitoring is associated with lower blood pressure and better control, with the largest benefits when combined with co-interventions¹⁴. It also calls home monitoring cost-effective compared with office monitoring or usual care in people with high office readings¹⁴. The 2025 guideline likewise pairs home monitoring with frequent contact with a care team, rather than presenting it as a stand-alone fix¹.

What the evidence does not show

It doesn’t show that a monitor lowers blood pressure by itself. In the meta-analysis, self-monitoring without co-interventions had little or no effect on blood pressure or control⁴. In four trials with little or no added support, ambulatory systolic pressure didn’t differ significantly from usual care⁴. The difference was +1.1 mm Hg (95% CI -0.3 to 2.5)⁴. The authors noted that self-monitoring may still have other benefits, such as engaging patients or reducing clinician workload, but the trials didn’t measure those⁴.

It doesn’t show effects on heart attacks, strokes or deaths. The meta-analysis measured blood pressure, not clinical events such as heart attacks or strokes⁴. The evidence linking white-coat hypertension to more cardiovascular events comes from observational studies³. The USPSTF says it’s unclear whether treating either white-coat or masked hypertension improves health outcomes, and calls that a critical evidence gap².

It mostly doesn’t cover healthy people checking blood pressure as a longevity habit. The trials enrolled people with hypertension⁴. The benefit was larger in people taking fewer blood pressure medicines, and in those with higher baseline systolic pressure, up to 170 mm Hg⁴. The effect on clinic systolic pressure was smaller in people with a history of stroke⁴.

That’s why the rating is Moderate. The trial evidence is large and fits guideline practice^{2, 4}. But results varied between trials, and the benefit depends on what’s done with the readings⁴. And that benefit was measured in blood pressure rather than clinical outcomes^{2, 4}.

How to choose a monitor: validated, upper-arm, right cuff size

The AHA recommends an automatic, cuff-style monitor that goes on the upper arm⁵. It doesn’t recommend wrist and finger monitors, because they give less reliable readings⁵. It also says to choose a validated monitor and, for older adults, pregnant people and children, to make sure it’s validated for them⁵. The USPSTF likewise describes home monitoring as measurement at the upper arm with a validated and accurate, fully automated device².

Validation means documented, independent accuracy testing under a recognized protocol⁷. In the US, the AMA supports a free US Blood Pressure Validated Device Listing at validatebp.org⁶. It has separate categories for home, wrist, office and other device types⁶.

To be listed, a device needs an active FDA 510(k) clearance and separate documentation of independent validation testing⁷. That documentation must come from a qualified third party or a peer-reviewed publication, under an accepted protocol such as ISO 81060-2⁷. Cuff sizes must have been tested with, and be available for, the intended population⁷. An independent review committee makes the final decision^{6, 7}. The AMA says it receives no funding from blood pressure device manufacturers for developing the listing process^{6, 7}.

Accuracy problems aren’t hypothetical. A Canadian study checked 85 adults’ own wrist or upper-arm home monitors against simultaneous two-observer auscultation with a mercury sphygmomanometer¹⁰. Average differences were acceptable, but 69% of devices differed from the reference by 5 mm Hg or more on systolic or diastolic pressure¹⁰. The gap was 10 mm Hg or more for 29% of devices, and 15 mm Hg or more for 7%¹⁰. Devices also tended to read higher relative to the reference as arm circumference increased¹⁰.

Cuff size matters too. The AHA advises measuring around your upper arm and choosing a monitor that comes with the correct cuff size⁵. In the Cuff(SZ) randomized crossover trial, 195 adults in Baltimore were measured with an automated device⁸. Compared with a correctly sized cuff, a regular adult cuff read systolic pressure about 3.6 mm Hg lower in people who needed a small cuff⁸. It read about 4.8 mm Hg higher in those who needed a large cuff, and about 19.5 mm Hg higher in those who needed an extra-large one⁸.

Cost can also matter. The 2020 AHA/AMA statement noted that coverage varied¹⁴. It also noted that relatively few private and commercial payers and Medicaid plans covered home monitoring for diagnosis and management¹⁴.

• The exact model, or a documented equivalent variant, is on the US Validated Device Listing at validatebp.org^{6, 7}
• An upper-arm cuff, not a wrist or finger device⁵
• A cuff that matches your measured upper-arm circumference^{5, 8}
• Built-in memory, or another way to keep readings to share at appointments⁵

How to take your blood pressure at home

Technique can shift a reading by several mm Hg. In the ARMS crossover randomized trial, 133 adults in Baltimore had readings taken with the arm in different positions⁹. Compared with an arm supported on a desk, resting it in the lap raised systolic readings by 3.9 mm Hg (95% CI 2.5 to 5.2)⁹. Letting it hang unsupported at the side raised them by 6.5 mm Hg (5.1 to 7.9)⁹. Diastolic readings were 4.0 mm Hg higher in the lap and 4.4 mm Hg higher at the side⁹.

The ARMS authors concluded that these common arm positions substantially overestimate blood pressure⁹. The AHA/AMA statement counts a standardized measurement and monitoring protocol as best practice, alongside validated devices and correctly sized cuffs¹⁴. The steps below draw on the AHA’s home instructions and the USPSTF’s description of seated readings after 5 minutes of rest^{2, 5}.

• Don’t smoke, drink caffeinated beverages or exercise within 30 minutes before measuring⁵
• Empty your bladder first⁵
• Sit and rest quietly for at least 5 minutes, and don’t talk or use the phone during the reading^{2, 5}
• Support your arm on a flat surface at heart level, not on your lap or hanging at your side^{5, 9}
• Put the cuff on bare skin, not over clothing, with its bottom edge just above the bend of the elbow⁵
• Take two readings one minute apart, at the same time each day⁵
• Write the readings down or keep them in the monitor’s memory⁵

Smartwatches and rings are not a substitute for a cuff

The 2025 AHA/ACC guideline says to avoid relying on cuffless devices, including smartwatches, for accurate blood pressure measurement until they demonstrate greater precision and reliability¹. A December 2025 AHA scientific statement on cuffless devices explains why¹¹. Most estimate blood pressure indirectly from optical or pressure sensors, often with machine learning¹¹. Most also need periodic calibration against a cuff, so their output often reflects change since calibration rather than a direct measurement¹¹.

Validation has gaps too. Most of it is done immediately after calibration, in static, controlled settings¹¹. There isn’t yet an ISO protocol for intermittent-measurement cuffless devices¹¹. Motion, posture and sensor placement can all affect results¹¹. Accuracy may also vary with skin tone, age, body size and health condition¹¹.

Regulatory status doesn’t settle the question. The AHA statement notes that some cuffless devices may be FDA cleared¹¹. It still calls checking a device’s validation status essential before clinical use¹¹.

In July 2025 the FDA sent a warning letter to the wearable maker WHOOP about its Blood Pressure Insights feature¹². The agency said blood pressure estimation is inherently associated with diagnosing low and high blood pressure¹². It said an erroneously low or high reading can have significant consequences, and that false reassurance could delay treatment¹².

In a June 2026 close-out letter, the FDA said it did not intend to enforce device requirements for the feature as modified¹³. That decision rested on changes WHOOP made to the feature and its labeling, and was consistent with the FDA’s updated general wellness guidance¹³. The letter doesn’t say the feature is cleared, approved or validated¹³.

Safety: the risk is a wrong number

The main risk of a home monitor is a misleading reading. A cuff that’s too small or an unsupported arm can push readings high and overstate blood pressure^{8, 9}. The ARMS authors warned that this could lead to misdiagnosis⁹. A cuff that’s too large or an inaccurate device can give readings that run low, which can be falsely reassuring^{8, 10}. Writing about a cuffless feature, the FDA warned that inappropriate reassurance from a wrong reading could delay treatment¹².

The AHA says home monitoring doesn’t replace regular visits with a clinician⁵. It suggests taking your stored readings to appointments⁵. It also advises against stopping blood pressure medication without checking with a healthcare professional⁵.

Sources

1. Top Things to Know: 2025 High Blood Pressure Guideline (2025 AHA/ACC multisociety guideline for the prevention, detection, evaluation and management of high blood pressure in adults) American Heart Association, 2025 · guideline
2. Hypertension in Adults: Screening (final recommendation statement) US Preventive Services Task Force, 2021 · guideline
3. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis Annals of Internal Medicine (Cohen JB et al.), 2019 · meta-analysis
4. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis PLOS Medicine (Tucker KL et al.), 2017 · meta-analysis
5. Monitoring your blood pressure at home American Heart Association, 2025
6. US Blood Pressure Validated Device Listing (VDL) American Medical Association (validatebp.org) · certifier
7. Device Validation and VDL Criteria American Medical Association (validatebp.org) · certifier
8. Effects of cuff size on the accuracy of blood pressure readings: the Cuff(SZ) randomized crossover trial JAMA Internal Medicine (Ishigami J et al.), 2023 · randomized trial
9. Arm position and blood pressure readings: the ARMS crossover randomized clinical trial JAMA Internal Medicine (Liu H et al.), 2024 · randomized trial
10. An assessment of the accuracy of home blood pressure monitors when used in device owners American Journal of Hypertension (Ringrose JS et al.), 2017
11. Top Things to Know: Cuffless devices for the measurement of blood pressure (AHA scientific statement, Cohen JB et al., Hypertension) American Heart Association, 2025
12. Warning letter: WHOOP, Inc. (MARCS-CMS 709755), July 14, 2025 US Food and Drug Administration, 2025 · regulator
13. Close-out letter: WHOOP, Inc. (MARCS-CMS 709755), June 17, 2026 US Food and Drug Administration, 2026 · regulator
14. Top Things to Know: Self-measured blood pressure monitoring at home (joint AHA/AMA policy statement, Shimbo D et al., Circulation) American Heart Association, 2020